{"componentChunkName":"component---src-templates-tag-template-js","path":"/author/conlon-nt","result":{"data":{"site":{"siteMetadata":{"title":"Bioinformatics Institute Publications","subtitle":"Repository of all published Science Articles by our Researchers, their Group Members and Collaborators."}},"allMarkdownRemark":{"edges":[{"node":{"fields":{"slug":"/posts/2020-01-16-preclinical-characteristics-of-the-irreversible-pan-her-kinase-inhibitor-neratinib-compared-with-lapatinib-implications-for-the-treatment-of-her2-positive-and-her2-mutated-breast-cancer/"},"frontmatter":{"title":"Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer","date":"2019-05-28T06:37:04.338Z","categories":["Atomistic Simulations and Design in Biology","Biomolecular Modelling and Design Division"],"description":"An estimated 15â€“20% of breast cancers overexpress human epidermal growth factor receptor 2 (HER2/ERBB2/neu). Two small-molecule tyrosine kinase inhibitors (TKIs), lapatinib and neratinib, have been approved for the treatment of HER2-positive (HER2+) breast cancer. "}}}]}},"pageContext":{"tag":"Conlon NT","currentPage":0,"postsLimit":8,"postsOffset":0,"prevPagePath":"/author/conlon-nt","nextPagePath":"/author/conlon-nt/page/1","hasPrevPage":false,"hasNextPage":false}}}